Oriented by Product Innovation, Dongtai Pharma Striving to Build a Global Characteristic Pharmaceutical Brand

The COVID-19 pandemic in 2020 is a huge test and challenge to Chinese pharmaceutical enterprises. Some have forged ahead, while others have encountered disastrous defeats. Founded in 2002, as a comprehensive and modern GMP pharmaceutical enterprise integrating scientific research, production, and sales, Henan Dongtai Pharmaceutical Co., Ltd. (“Tongtai Pharma”) has stood the impacts of COVID-19 pandemic and stood out through its nearly two decades of continuous innovation and development and multiple core technologies with independent intellectual property rights, with API and pharmaceutical intermediate R&D, production and sales not much affected by the pandemic. The company continues to provide quality products and services to Chinese and overseas customers by strictly following ICHQ7 and GMP guidelines.

Dongtai Pharma mainly produces diclofenac sodium series nonsteroidal anti-inflammatory products, with five best-selling products including diclofenac sodium, diclofenac potassium, aceclofenac, rimantadine hydrochloride, and acemetacin. Wherein, its technology application project of diclofenac sodium won the “Second Prize of National Science and Technology Progress Award” and provides more advanced technical support to the improvement of diclofenac sodium drug production level, which is noteworthy.

Dongtai Pharma has comprehensively transformed the production unit for the important intermediate 2,6-dichlorodiphenylamine using its unique patented new process and technical plan. In terms of new technology support, it has completed a diclofenac production line that meets China’s national emission standards, without residual solvent of products and with product quality, production process, inspection means, and storage and transportation, etc. all meeting China’s national certification standards. The production line after the transformation reaches annual production of 3,000 tons, accounting for more than 70% of the total production in the world.

Good processes lead to high-quality products. Its diclofenac series products have received international quality recognition and passed the certification of 5 systems in the world (EU CEP certificate, Japan GMP certificate, U.S. FDA inspection certificate, ISO certificate, and South Korea GMP certificate) as well as the Chinese GMP certification. Dongtai Pharma has become an important R&D, production and export base of diclofenac products in the world, with more than 70% of the products exported to Europe, North America, South America, Southeast Asia, Japan, South Korea, and other countries and regions, enjoying a good reputation in the international market.

Dongtai Pharma is one of the Chinese pharmaceutical enterprises going global. China will gradually grow from a big country in pharmaceuticals to a power in pharmaceuticals as tens of millions of Chinese pharmaceutical enterprises continue to work hard on innovation. Adhering to market demands as the core and product innovation as the orientation and industry-university-research combination, Dongtai Pharma strives to achieve human health and social progress and build itself into a global characteristic pharmaceutical brand through its outstanding innovation ability!

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.